Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$8.06
-0.15-1.83%
Pre-Market: 6:54 AM EDT
Comments
Loading...
Zevra Therapeutics Analyst Ratings and Price Targets | NASDAQ:ZVRA | Benzinga
Zevra Therapeutics Inc has a consensus price target of $21.44 based on the ratings of 11 analysts. The high is $25 issued by Canaccord Genuity on March 13, 2025. The low is $17 issued by JMP Securities on September 24, 2024. The 3 most-recent analyst ratings were released by Canaccord Genuity, Guggenheim, and HC Wainwright & Co. on March 13, 2025, respectively. With an average price target of $22.33 between Canaccord Genuity, Guggenheim, and HC Wainwright & Co., there's an implied 177.09% upside for Zevra Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Guggenheim
HC Wainwright & Co.
Citizens Capital Markets
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Zevra Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/13/2025 | Buy Now | 210.17% | Canaccord Genuity | Sumant Kulkarni43% | $23 → $25 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 172.95% | Guggenheim | Eddie Hickman63% | $20 → $22 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 148.14% | HC Wainwright & Co. | Oren Livnat61% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 123.33% | Citizens Capital Markets | Jason Butler56% | $17 → $18 | Maintains | Market Outperform | Get Alert |
| 03/12/2025 | Buy Now | 210.17% | Cantor Fitzgerald | Kristen Kluska70% | $25 → $25 | Reiterates | Overweight → Overweight | Get Alert |
| 11/20/2024 | Buy Now | 148.14% | HC Wainwright & Co. | Oren Livnat61% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 185.36% | Canaccord Genuity | Sumant Kulkarni43% | $25 → $23 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen59% | — | Reiterates | → Overweight | Get Alert |
| 10/07/2024 | Buy Now | 148.14% | Guggenheim | — | → $20 | Initiates | → Buy | Get Alert |
| 10/01/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen59% | — | Reiterates | → Overweight | Get Alert |
| 09/30/2024 | Buy Now | 148.14% | HC Wainwright & Co. | Oren Livnat61% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/24/2024 | Buy Now | 110.92% | JMP Securities | Jason Butler56% | → $17 | Initiates | → Market Outperform | Get Alert |
| 09/24/2024 | Buy Now | 210.17% | Maxim Group | Jason McCarthy42% | $18 → $25 | Maintains | Buy | Get Alert |
| 09/24/2024 | Buy Now | 160.55% | Roth MKM | Jonathan Aschoff34% | $19 → $21 | Maintains | Buy | Get Alert |
| 09/20/2024 | Buy Now | 148.14% | HC Wainwright & Co. | Oren Livnat61% | $18 → $20 | Maintains | Buy | Get Alert |
| 09/18/2024 | Buy Now | 172.95% | Canaccord Genuity | Sumant Kulkarni43% | $24 → $22 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen59% | — | Reiterates | → Overweight | Get Alert |
| 08/05/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen59% | — | Reiterates | → Overweight | Get Alert |
| 08/05/2024 | Buy Now | 123.33% | HC Wainwright & Co. | Oren Livnat61% | $15 → $18 | Maintains | Buy | Get Alert |
| 07/09/2024 | Buy Now | 86.1% | HC Wainwright & Co. | Oren Livnat61% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 86.1% | HC Wainwright & Co. | Oren Livnat61% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen59% | — | Reiterates | → Overweight | Get Alert |
| 03/12/2024 | Buy Now | — | William Blair | Tim Lugo34% | — | Initiates | → Outperform | Get Alert |
| 03/05/2024 | Buy Now | 86.1% | HC Wainwright & Co. | Oren Livnat61% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 12/28/2023 | Buy Now | 86.1% | HC Wainwright & Co. | Oren Livnat61% | $10 → $15 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 197.77% | Canaccord Genuity | Sumant Kulkarni43% | $20 → $24 | Maintains | Buy | Get Alert |
| 10/06/2023 | Buy Now | 210.17% | Roth MKM | Jonathan Aschoff34% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 09/01/2023 | Buy Now | 148.14% | Canaccord Genuity | Sumant Kulkarni43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 148.14% | Canaccord Genuity | Sumant Kulkarni43% | $19 → $20 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 48.88% | Maxim Group | Jason McCarthy42% | → $12 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Zevra Therapeutics (ZVRA) stock?
The latest price target for Zevra Therapeutics (NASDAQ:ZVRA) was reported by Canaccord Genuity on March 13, 2025. The analyst firm set a price target for $25.00 expecting ZVRA to rise to within 12 months (a possible 210.17% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zevra Therapeutics (ZVRA)?
The latest analyst rating for Zevra Therapeutics (NASDAQ:ZVRA) was provided by Canaccord Genuity, and Zevra Therapeutics maintained their buy rating.
When was the last upgrade for Zevra Therapeutics (ZVRA)?
There is no last upgrade for Zevra Therapeutics
When was the last downgrade for Zevra Therapeutics (ZVRA)?
There is no last downgrade for Zevra Therapeutics.
When is the next analyst rating going to be posted or updated for Zevra Therapeutics (ZVRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zevra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zevra Therapeutics was filed on March 13, 2025 so you should expect the next rating to be made available sometime around March 13, 2026.
Is the Analyst Rating Zevra Therapeutics (ZVRA) correct?
While ratings are subjective and will change, the latest Zevra Therapeutics (ZVRA) rating was a maintained with a price target of $23.00 to $25.00. The current price Zevra Therapeutics (ZVRA) is trading at is $8.06, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.